

February 22, 2023
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notification of Amendment to the Articles of Incorporation

SymBio Pharmaceuticals Limited (the “Company”) announced that, pursuant to the resolution passed by the Company’s Board of Directors today, a proposal regarding Amendment of the Articles of Incorporation will be submitted to the 18th Annual General Meeting of Shareholders scheduled to be held on March 23, 2023.

1. Purpose of the Amendment to the Articles of Incorporation

As part of our global business strategy centered around the development of brincidofovir (“BCV”), the Company is conducting multiple clinical trials for viral infections in the transplantation area aiming to develop BCV to its potential and deliver new treatments in therapeutic areas with no existing treatment options. In addition, non-clinical studies are underway in promising areas of oncology and hematology, including brain tumors and NK/T cell lymphoma, and for neurodegenerative diseases such as multiple sclerosis and Alzheimer's disease, and we will proceed to clinical trials in these therapeutic areas after confirming POC (Proof of Concept).

In parallel with our research and development progress, it is a priority to build an appropriate organizational structure for the creation of a global specialty pharmaceutical company.

Assuming future funding needs, in addition to allocating internal funds, the Company is considering the medium- to long-term possibility of exploring business alliances with global pharmaceutical companies and raising funds.

To enable the Company to implement a flexible and agile capital policy in the future, the amendment will be proposed to increase the total number of authorized shares in advance. As of December 31, 2022, the Company’s had 39,600,000 shares outstanding out of a total of 41,750,000 authorized shares.

2. Details of the proposed amendment

(Text to be amended and the proposed amended text are shown underlined.)

Current Articles of Incorporation	Proposed Change
Articles 6 (Authorized Shares) The company is authorized to issue <u>41,750,000</u> shares.	Articles 6 (Authorized Shares) The company is authorized to issue <u>65,000,000</u> shares.

3. Schedule

Date of Annual General Meeting of Shareholders to amend the Articles of Incorporation: March 23, 2023

Effective date of the amendment: March 23, 2023

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125